Xtant Medical Holdings, Inc. has completed the sale of certain businesses to Companion Spine for approximately $19.2 million, consisting of $11.0 million in cash and $8.2 million in short-term seller financing through an unsecured promissory note maturing on January 15, 2026. The operating contributions of the divested assets and entities will be included in Xtant's results through their December 1, 2025 date of sale. Xtant plans to use the net proceeds from the transaction to reduce long-term debt and enhance cash liquidity. The company stated that this move will allow it to focus on its core biologics business and continue operations without the need for additional external capital.